ACRO Biomedical Co., Ltd. (6748) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of ACRO Biomedical Co., Ltd. TWD 370, price TWD 241, upside +53.4%, quality 16 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch ACRO Biomedical Co., Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Sep 24, 2026.
How to read this chart
10‑month range 59.80 TWD – 295.50 TWD · fair‑value band 243.96 TWD – 462.07 TWD · the 241.00 TWD price screens below the 369.71 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Sep 24, 2026.
Follow ACRO Biomedical Co. in your weekly email
Every Wednesday you see whether ACRO Biomedical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
ACRO Biomedical Co., Ltd. develops medical-grade regenerative biomaterials. The company offers products in the areas of wound care, orthopedics, dentistry, ophthalmology, cosmetic micro plastic surgery, beauty and eye care, and tissue engineering and regenerative medicines. The company was founded in 2014 and is based in Kaohsiung, Taiwan.
Stock analysis
ACRO Biomedical Co., Ltd. (6748) currently trades at 241.00 TWD, while our model-based Fair Value estimate is 369.71 TWD, implying the stock looks roughly 34.8% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: 243.96 TWD (bear) to 462.07 TWD (bull), the price of 241.00 TWD sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 16/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
ACRO Biomedical Co., Ltd. reported revenue of 38.3M TWD in FY2025 versus 21.8M TWD in FY2021, a compound +15.1%/yr. Reported net income was −82.7M TWD in FY2025.
Key figures
Market cap 17.2B TWD (≈ $539M) · EPS (TTM) −1.35 TWD · Net margin −216% · Return on equity −9.6% · Return on assets (EBIT) −15.3% · Operating margin −188% · Revenue (TTM) 38.3M TWD · Revenue growth (YoY) +7.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 53%, 6748 screens cheaper than that median.
Fair Value models
Bear 243.96 TWDFair Value 369.71 TWDBull 462.07 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.32/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−13.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.2%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−310.4% (2020) → −242.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare ACRO Biomedical Co., Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 648 stocks
Beats the industry median on 4/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score24 · Bottom 25%
Fair Value upside+53% · Top 25%
Profitability
Return on assets−6% · Above median
Operating margin (TTM)−188% · Bottom 25%
Growth and dividend
Revenue growth8% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is ACRO Biomedical Co., Ltd. (6748) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 369.71 TWD versus a price of 241.00 TWD, about +53% upside (undervalued).
What is the fair value of 6748?
Our model-based fair value for ACRO Biomedical Co., Ltd. is 369.71 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 241.00 TWD.
What is the quality score of 6748?
ACRO Biomedical Co., Ltd. has a Quality Score of 16/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ACRO Biomedical Co., Ltd. (6748)?
Our model-based price target is the fair value of 369.71 TWD (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 243.96 TWD, optimistic scenario 462.07 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the ACRO Biomedical Co., Ltd. stock forecast for 2026?
Our models put fair value at 369.71 TWD, about +53% upside versus a price of 241.00 TWD (undervalued). Cautious scenario 243.96 TWD, optimistic scenario 462.07 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of ACRO Biomedical Co., Ltd. (6748)?
ACRO Biomedical Co., Ltd. reported trailing-twelve-month revenue of about 38.3M TWD (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of ACRO Biomedical Co., Ltd. (6748)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ACRO Biomedical Co., Ltd. it is 369.71 TWD per share (as of Sep 24, 2026), against a price of 241.00 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is ACRO Biomedical Co., Ltd. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6748 trades below its calculated fair value: price 241.00 TWD, fair value 369.71 TWD, a gap of about +53% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6748?
No. The price is what the market pays today (241.00 TWD); the fair value is what the company's own numbers justify (369.71 TWD). For ACRO Biomedical Co., Ltd. the two are 128.71 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is ACRO Biomedical Co., Ltd. worth?
The market values ACRO Biomedical Co., Ltd. at about 17.2B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 241.00 TWD; our models calculate a fair value of 369.71 TWD per share.
What do the bullish and bearish scenarios say about 6748?
Our models span a range for ACRO Biomedical Co., Ltd.: cautious scenario 243.96 TWD, base 369.71 TWD, optimistic 462.07 TWD per share (as of Sep 24, 2026, price 241.00 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ACRO Biomedical Co., Ltd. (6748)?
Balance-sheet figures for ACRO Biomedical Co., Ltd. (as of Sep 24, 2026): return on equity −9.6%. They feed the Quality Score of 16/100, which measures business quality independently of the share price.
Which stocks are comparable to ACRO Biomedical Co., Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ACRO Biomedical Co., Ltd. stock attractive at the current price?
The data as of Sep 24, 2026: price 241.00 TWD, calculated fair value 369.71 TWD (+53%), Quality Score 16/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6748 calculated?
We run ACRO Biomedical Co., Ltd. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 369.71 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. ACRO Biomedical Co., Ltd. currently trades 53 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ACRO Biomedical Co., Ltd. (6748)?
The closing price on Sep 23, 2026 was 241.00 TWD. Our model-based fair value is 369.71 TWD, about +53% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ACRO Biomedical Co., Ltd. right now?
The large discount to fair value meets weak quality (16/100). That raises the risk this is a value trap rather than a bargain. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (243.96 TWD to 462.07 TWD) leaves room in how you read the outcome.
Key figures of ACRO Biomedical Co., Ltd.
How large is the market capitalisation of ACRO Biomedical Co., Ltd. (6748)?
The market capitalisation of ACRO Biomedical Co., Ltd. is 17.2B TWD (≈ $539M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of ACRO Biomedical Co., Ltd. (6748)?
Earnings per share at ACRO Biomedical Co., Ltd. are −1.35 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of ACRO Biomedical Co., Ltd. (6748)?
The net margin of ACRO Biomedical Co., Ltd. is −216% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ACRO Biomedical Co., Ltd. (6748)?
The return on equity (ROE) of ACRO Biomedical Co., Ltd. is −9.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ACRO Biomedical Co., Ltd. (6748)?
On an EBIT basis the return on assets of ACRO Biomedical Co., Ltd. is −15.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ACRO Biomedical Co., Ltd. (6748)?
The operating margin of ACRO Biomedical Co., Ltd. is −188% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ACRO Biomedical Co., Ltd. (6748)?
Revenue at ACRO Biomedical Co., Ltd. is growing +7.6% versus a year earlier (3y avg +11.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does ACRO Biomedical Co., Ltd. (6748) generate?
The free cash flow of ACRO Biomedical Co., Ltd. is −63.0M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does ACRO Biomedical Co., Ltd. (6748) hold?
ACRO Biomedical Co., Ltd. holds more cash than debt, 176M TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch ACRO Biomedical Co., Ltd. in the live analysis
One click puts ACRO Biomedical Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
